Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis [0.03%]
seladelpar治疗原发性胆汁性胆管炎的现实世界临床经验研究通讯
Selena Z Kuo,Jeffrey Yin,Rohit Loomba
Selena Z Kuo
Seladelpar recently received accelerated FDA approval for the treatment of primary biliary cholangitis (PBC) but there is limited knowledge regarding its efficacy in real-world clinical practice. This is a study of a cohort of adults with P...
Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S. Claims-Based Study [0.03%]
美国基于索赔的研究：低结核病发病率地区20705例炎症性肠病患者使用生物制剂和Janus激活剂的风险
Dhruv Ahuja,Kuan-Hung Yeh,Sagar B Patel et al.
Dhruv Ahuja et al.
We conducted a USA claims-based cohort study in 20,705 patients with inflammatory bowel diseases (IBD) on advanced therapies to estimate the overall and comparative risk of tuberculosis between advanced therapies using inverse probability o...
Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis [0.03%]
乙型肝炎相关失代偿期肝硬化患者中不稳定的反复代偿状态是一种中间表型
Shuai Xia,Zhiying He,Xiaoning Wu et al.
Shuai Xia et al.
Background and aim: Recent studies show that patients with hepatitis B virus (HBV)-related decompensated cirrhosis who achieve recompensation can still experience further decompensation, suggesting that recompensation sta...
Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [0.03%]
非肥胖和肥胖代谢性肝病患者的遗传风险因素导致肝纤维化差异研究
Kaleb Tesfai,Luis Antonio Díaz,Juan Pablo Arab et al.
Kaleb Tesfai et al.
Introduction: Previous studies have revealed conflicting results regarding liver fibrosis risk in lean metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to compare the risk of significant fibrosis...
High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients [0.03%]
炎症性肠病患者重度异型增生后 colorectal cancer 的高风险
Monica E W Derks,Maarten Te Groen,Lauranne A A P Derikx et al.
Monica E W Derks et al.
Background: There are limited data on colorectal cancer (CRC) risk after high-grade dysplasia in inflammatory bowel disease. Aims: To d...
Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease [0.03%]
合并炎症性肠病和慢性肝病的孕妇及其围生期结局
Jessica D Lee,Konstantinos Papamichael,Lauren T Grinspan et al.
Jessica D Lee et al.
Background: Inflammatory bowel disease (IBD) and chronic liver disease (CLD) are each associated with adverse pregnancy outcomes, but the impact of coexisting IBD and CLD on pregnancy remains understudied. ...
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial [0.03%]
肠道选择性甲状腺激素受体β激动剂Resmetirom对伴发代谢异常的非酒精性脂肪肝病患者的影响：MAESTRO-NASH研究的二次分析（体重或糖尿病变化亚组）
Mazen Noureddin,Mary Rinella,Rebecca Taub et al.
Mazen Noureddin et al.
Background: MAESTRO-NASH, a randomised, double-blind, placebo-controlled, 54-month phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed metabolic-dysfunction associated steatohepatitis (MA...
Research Communication: Teriflunomide Does Not Affect Gluten-Specific T-Cell Activity in Coeliac Disease-A Randomised, Placebo-Controlled Trial [0.03%]
特利氟米特不影响乳糜泻患者的 gluten 特异性 T 淋巴细胞活性：一项随机、双盲、安慰剂对照试验
Louise F Risnes,Margit Brottveit,Ida Robertsen et al.
Louise F Risnes et al.
Coeliac disease is an autoimmune disorder driven by gluten and managed through a strict gluten-free diet. We tested teriflunomide, a drug known for its ability to alter T-cell activity, in a phase 2a trial of 15 patients with coeliac diseas...
Treatment-Free Outcomes Following Surgery for IBD: A Nationwide Cohort Study [0.03%]
一项针对IBD手术患者的无治疗结局的全国队列研究
Adam S Faye,Jordan Axelrad,Jiangwei Sun et al.
Adam S Faye et al.
Background: Surgery in select individuals with inflammatory bowel disease (IBD) may obviate the need for future IBD-related treatment. Aims: ...
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non-Cirrhotic Patients [0.03%]
东亚太平洋地区慢性肝病病因变化及非肝硬化患者肝癌筛查研究通讯
Ming Liu,Chuan Liu,Tsz Ngai Mok et al.
Ming Liu et al.
East Asia Pacific (EAP) faces a high burden of chronic liver disease (CLD), with metabolic dysfunction-associated steatotic liver disease (MASLD) projected to account for about 80% of CLD prevalence by 2040. Using Global Burden of Disease 2...